Omnicell, Inc.

37th Annual J.P. Morgan Healthcare Conference

January 9, 2019

Randall A. Lipps Peter Kuipers

Chairman, President Chief Financial Officer

Chief Executive Officer,
Founder

© 2019 Omnicell, Inc. Content is confidential and proprietary 1

Safe Harbor Statement
This presentation contains certain “forward-looking” statements. These statements are based on the current estimates and
assumptions of the management of Omnicell, Inc. (or “Omnicell” or “the Company”) as of the date of this presentation and are
naturally subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance on
these forward-looking statements. Actual results may vary materially from the expectations contained herein. When used herein, the
words “may”, “will”, “should”, “could”, “would”, “plan”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “potential” and “expect” and
similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to risks,
uncertainties, assumptions and other factors that may cause the actual results of Omnicell to be materially different from those
reflected in such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated
by such forward-looking statements include, among others, those set forth under the headings “Note Regarding Forward-Looking
Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the
form 10K filed February 27, 2018. Except to the extent required by applicable securities laws, Omnicell is not under any obligation to
(and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future
events, or otherwise. All statements contained in this presentation are made only as of the date of this presentation.

Use of Non-GAAP Financial Measures

In our earnings releases, conference calls, slide presentations, or webcasts, we may use or discuss non-GAAP financial measures
as defined by Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or
discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial
measure, is available within our public filings with the Securities and Exchange Commission, available on the Investors section of
our website at http://www.omnicell.com.

© 2019 Omnicell, Inc. Content is confidential and proprietary 2

Our Path to Medication Management Leadership

A Leader in
Medication
Management

© 2019 Omnicell, Inc. Content is confidential and proprietary 3

3000% Increase in Administrators since 1970

© 2019 Omnicell, Inc. Content is confidential and proprietary 4

Radical Change Needed in Pharmacy Care Delivery

76% Non-clinical Activities

$450 Billion annual spend … with suboptimal outcomes6

6. iQVIA Institute report (2018). Medicine Use & spending in the U.S.

© 2019 Omnicell, Inc. Content is confidential and proprietary 5

© 2019 Omnicell, Inc. Content is confidential and proprietary 6
Omnicell Products

© 2019 Omnicell, Inc. Content is confidential and proprietary 7

Omnicell Platform Drives Value in Many Areas

XR2 : 0% dispensing error
IV Compounding Robots : 66%
lower costs
Compared to outsourcing
90% adherence
ADCs : saves nursing 74.2% of performance rate
time to identify controlled
substance discrepancies
Increased Rx volume

Intelligence + Automation drives 2–3% reduction

of medication costs

© 2019 Omnicell, Inc. Content is confidential and proprietary 8

 Performance Center

Reduce
Medication
Costs by

2-3%

© 2019 Omnicell, Inc. Content is confidential and proprietary 9

 XR2 Automated Central Pharmacy System

Dispensing Errors
* First group of hospital system customers

© 2019 Omnicell, Inc. Content is confidential and proprietary 10

 IV Compounding IVX Workflow
Robots

Reduction in IV Costs
* Compared to outsourcing

© 2019 Omnicell, Inc. Content is confidential and proprietary 11

 Multimed Adherence Packaging

Adherence Performance Rate

* At home

© 2019 Omnicell, Inc. Content is confidential and proprietary 12

Healthcare Market Trends & Omnicell Solutions Are Strongly Aligned

Omnicell Solution
Healthcare Trend Market Need
Strength

Health systems consolidation Integrated & automated 60% of top health systems are
horizontally systems customers… broadest portfolio

Pharmacy becoming More sophisticated ROI Clear innovation leader and

more strategic based solutions strategic partner choice

Provider – Payor vertical Increased need for Population Emerging broadest portfolio
integration health solutions across continuum of care

© 2019 Omnicell, Inc. Content is confidential and proprietary 13

Financial Success

Annual GAAP Revenue ($M) Types of Revenue

Capital
Equipment &
Software

60%
Recurring
Consumables

11%

Recurring Service
* 2018 guidance
29%
Consistent growth through expanding platform and loyal
customer base

© 2019 Omnicell, Inc. Content is confidential and proprietary 14

Significant Growth Runway: Long Term Financial Framework

Organic Revenue Growth Non-GAAP

Revenue Growth from M&A Operating Margin

between 8% and 12% 5% on average 15% excluding

per year per year integration expenses

© 2019 Omnicell, Inc. Content is confidential and proprietary 15

© 2019 Omnicell, Inc. Content is confidential and proprietary 16